Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria
Europace · 2025
DOI: 10.1093/europace/euaf080 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Europace, 2025. Verfasst von Paulus Kirchhof und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Dronedarone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Aims
This post-hoc analysis of the ATHENA trial assessed whether dronedarone (400 mg twice daily) improved cardiovascular outcomes compared with placebo in patients with early atrial fibrillation/atrial flutter (AF) and cardiovascular comorbidities, based on EAST-AFNET 4 inclusion criteria and outcomes. Methods and results The co-primary outcomes were (i) a composite of cardiovascular death, stroke, or hospitalisation due to worsening of heart failure (HF) or acute coronary syndrome (ACS) and (ii) nights spent in hospital per year. Sinus rhythm (SR) at 12 months was a secondary outcome. The primary safety outcome was a composite of death, stroke, or pre-specified serious adverse events of special interest (AESIs) related to rhythm control therapy. 1810 patients with early AF were identified. Patients receiving dronedarone had fewer deaths from cardiovascular causes, strokes, or hospitalisations due to worsening of HF or ACS compared with patients receiving placebo [dronedarone (n = 924), 87 patients with ≥1 event; placebo (n = 886), 117 patients with ≥1 event; hazard ratio 0.71; 95% confidence interval 0.54–0.94; P = 0.014]. Number of nights spent in hospital did not differ between treatment groups. More patients receiving dronedarone (69.2%) were in SR at 12 months compared with placebo (60.8%). Primary safety events comprising death, stroke, or pre-specified serious AESIs related to rhythm control therapy were not different (dronedarone vs. placebo: 60 vs. 71 patients with ≥1 event).
Conclusion
These data support the use of dronedarone for early rhythm control therapy in selected patients with early AF.
Trial registration
ATHENA: ClinicalTrials.gov identifier NCT00174785. EAST-AFNET 4: ClinicalTrials.gov identifier NCT01288352.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- German Center for Cardiovascular Research, Partner Site Hamburg/Kiel/Lübeck, Germany.
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
- Institute of Molecular and Clinical Sciences, St. George's University of London, London, UK.
- Maastricht University Medical Centre and Cardiovascular Research Institute, Maastricht, The Netherlands.
- Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC, USA.
ORCID-Profile: Paulus Kirchhof, A John Camm, Harry J G M Crijns, Jonathan P Piccini, Christian Torp-Pedersen, David S McKindley, Mattias Wieloch, Stefan H Hohnloser
Förderung
- Sanofi
Zitieren
APA
Kirchhof, P., Camm, A. J., Crijns, H. J. G. M., Piccini, J. P., Torp-Pedersen, C., McKindley, D. S., Wieloch, M., & Hohnloser, S. H. (2025). Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. Europace. https://doi.org/10.1093/europace/euaf080
Vancouver
Kirchhof P, Camm AJ, Crijns HJGM, Piccini JP, Torp-Pedersen C, McKindley DS, et al. Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria. Europace. 2025. doi:10.1093/europace/euaf080
BibTeX
@article{Kirchhof2025,
author = {Kirchhof, Paulus and Camm, A John and Crijns, Harry J G M and Piccini, Jonathan P and Torp-Pedersen, Christian and McKindley, David S and Wieloch, Mattias and Hohnloser, Stefan H},
title = {Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf080}
}
EUVIMED